Park Ha Biological Technology Co. Ltd. Faces Nasdaq Delisting Risk Due to Bid Price Deficiency, Given Until March 2026 to Regain Compliance
Park Ha Biological Technology Co. Ltd. has received notifications from Nasdaq regarding its failure to meet requirements related to minimum bid price and market value of listed securities. As of September 2, 2025, the company's ordinary shares have been trading below the necessary $1 per share for 30 consecutive business days, and its market value has fallen below $35 million. The company has until March 2, 2026, to regain compliance. If it fails to do so, it may qualify for an additional 180-day compliance period to address these deficiencies, potentially through measures such as a reverse stock split. Currently, there are no immediate effects on its listing or trading status.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Park Ha Biological Technology Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-084997), on September 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.